This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roy, J. Articles by Tremblay, M. J. Search for Related Content PubMed PubMed Citation Articles by Roy, J. Articles by Tremblay, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2002, p. 3447-3455, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3447-3455.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication

Centre de Recherche en Infectiologie, Hôpital CHUL, Centre Hospitalier Universitaire de Québec, and Département de Biologie Médicale, Faculté de Médecine, Université Laval, Ste-Foy, Québec, Canada G1V 4G2

Received 8 January 2002/ Returned for modification 21 March 2002/ Accepted 16 August 2002

The immunosuppressive macrolide rapamycin is used in humans to prevent graft rejection. This drug acts by selectively repressing the translation of proteins that are encoded by an mRNA bearing a 5'-polypyrimidine tract (e.g., ribosomal proteins, elongation factors). The human immunodeficiency virus type 1 (HIV-1) carries a polypyrimidine motif that is located within the tat exon 2. Treatment of human T lymphoid cells with rapamycin resulted in a marked diminution of HIV-1 transcription when infection was performed with luciferase reporter T-tropic and macrophage-tropic viruses. Replication of fully infectious HIV-1 particles was abolished by rapamycin treatment. The rapamycin-mediated inhibitory effect on HIV-1 production was reversed by FK506. The anti-HIV-1 effect of rapamycin was also seen in primary human cells (i.e., peripheral blood lymphocytes) from different healthy donors. Rapamycin was shown to diminish basal HIV-1 long terminal repeat gene expression, and the observed effect of rapamycin on HIV-1 replication seems to be independent of the virus-specific transactivating Tat protein. A constitutive ß-actin promoter-based reporter gene vector was unaffected by rapamycin treatment. Kinetic virus infection studies and exposure to reporter viruses pseudotyped with heterologous envelope proteins (i.e., amphotropic murine leukemia virus and vesicular stomatitis virus G) suggested that rapamycin is primarily affecting the life cycle of HIV-1 at a transcriptional level. Northern blot analysis confirmed that this compound is selectively targeting HIV-1 mRNA synthesis.

This article has been cited by other articles:

• Heredia, A., Gilliam, B., Latinovic, O., Le, N., Bamba, D., DeVico, A., Melikyan, G. B., Gallo, R. C., Redfield, R. R. (2007). Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro. Antimicrob. Agents Chemother. 51: 2489-2496 [Abstract] [Full Text]  
• Abbott, K. C., Swanson, S. J., Agodoa, L. Y.C., Kimmel, P. L. (2004). Human Immunodeficiency Virus Infection and Kidney Transplantation in the Era of Highly Active Antiretroviral Therapy and Modern Immunosuppression. J. Am. Soc. Nephrol. 15: 1633-1639 [Abstract] [Full Text]  
• Heredia, A., Amoroso, A., Davis, C., Le, N., Reardon, E., Dominique, J. K., Klingebiel, E., Gallo, R. C., Redfield, R. R. (2003). Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV {beta}-chemokines: An approach to suppress R5 strains of HIV-1. Proc. Natl. Acad. Sci. USA 100: 10411-10416 [Abstract] [Full Text]